Prostate cancer is the second leading cause of cancer deaths among males in the United States. While effective treatments exist for as long as the tumors remain sensitive to androgens, there are no good therapies available once evolution to an androgen-insensitive state occurs. An evaluation of factors which contribute to the growth of these later stage tumors is crucial to the development of new therapeutic strategies. Prolactin (PRL) is one such factor. Although large quantities of PRL are produced by the pituitary, PRL also serves as an autocrine growth factor in the normal human prostate and, as we have shown, this autocrine growth loop continues to be operative in cells representative of highly metastatic, androgen-independent cancers. Using a novel PRL growth antagonist developed in our laboratory, S179D PRL, we have demonstrated that blockade of the PRL autocrine growth loop reduces both the growth of well-established tumors and tumor initiation when androgen-independent cancer cells are grown in nude mice. This PRL growth antagonist therefore has the potential to be an important new therapeutic for late stage disease. The overall aim of the proposed project is to gain a fuller understanding of the molecular and cellular mechanisms underlying S179D PRL's antagonism of prostate tumor growth so that the full potential of this therapeutic can be realized.
The specific aims are 1) to determine the optimal dose of S179D PRL, 2) to establish whether S179D PRL slows or halts growth or actually reduces tumor size, 3) to determine whether resistance can develop, and 4) to determine whether any aspect of the growth inhibition involves a) the promotion of apoptosis, or b) downregulation of the growth-promoting PRL autocrine loop, or c) upregulation of the short PRL receptor. In most experiments tumor size will be monitored by the amount of a secreted transfected gene product in the urine. In this way, individual nude mice can be assessed for their response to treatment. S179D PRL will be administered by Alzet minipumps implanted subcutaneously. Molecular and cellular effects on the tumors/tumor cells will be assessed by end-labeling for apoptosis, Northern, Western and microarray analysis for gene expression and immunoprecipitation, Western and radiolabel incorporation for signaling.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK061005-03
Application #
6649850
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (O1))
Program Officer
Mullins, Christopher V
Project Start
2001-09-30
Project End
2005-06-30
Budget Start
2003-09-01
Budget End
2004-06-30
Support Year
3
Fiscal Year
2003
Total Cost
$255,731
Indirect Cost
Name
University of California Riverside
Department
Type
Schools of Medicine
DUNS #
627797426
City
Riverside
State
CA
Country
United States
Zip Code
92521
Tan, Dunyong; Chen, KuanHui E; Deng, Changhui et al. (2014) An N-terminal splice variant of human Stat5a that interacts with different transcription factors is the dominant form expressed in invasive ductal carcinoma. Cancer Lett 346:148-57
Huang, Kuang-tzu; Walker, Ameae M (2010) Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity. Prostate 70:37-47
Ueda, Eric K M; Soares, Carlos R J; Bartolini, Paolo et al. (2009) A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin. Biochemistry 48:6887-97
Guzman, Esther A; Langowski, John L; De Guzman, Ariel et al. (2008) S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells. Mol Cell Endocrinol 280:6-12
Tan, Dunyong; Huang, Kuang Tzu; Ueda, Eric et al. (2008) S2 deletion variants of human PRL receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain. Biochemistry 47:479-89
Walker, Ameae M (2007) S179D prolactin: antagonistic agony! Mol Cell Endocrinol 276:1-9
Wu, Wei; Zanello, Laura; Walker, Ameae M (2007) S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Prostate 67:1498-506
Wu, Wei; Walker, Ameae M (2006) Human chorionic gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes human prostate carcinoma cell migration and invasion. Cancer 106:68-78
Ueda, Eric; Ozerdem, Ugur; Chen, Yen-Hao et al. (2006) A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr Relat Cancer 13:95-111
Wu, Wei; Chen, Yen-Hao; Ueda, Eric et al. (2006) Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol Res 16:75-84

Showing the most recent 10 out of 19 publications